WPC
VRTX icon

Waters Parkerson & Co’s Vertex Pharmaceuticals VRTX Stock Holding History

Waters Parkerson & Co’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-489
Closed -$218K – 188
2025
Q2 		$218K Hold
489
– – 0.01% 177
2025
Q1 		$237K Buy
+489
New +$228K 0.01% 174
2024
Q4 		– Sell
-462
Closed -$215K – 195
2024
Q3 		$215K Hold
462
– – 0.01% 187
2024
Q2 		$217K Buy
+462
New +$201K 0.01% 172

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Waters Parkerson & Co's VRTX Position: Q3 2025 in Review

Waters Parkerson & Co sold out of Vertex Pharmaceuticals (VRTX) in Q3 2025, closing a stake of 489 shares — an estimated $218K sold.

Waters Parkerson & Co first reported a position in VRTX in Q2 2024 and held it in 4 quarters. The position peaked at $237K in Q1 2025. 1,519 funds tracked by Wall St. Rank hold VRTX as of Q3 2025.

  • Waters Parkerson & Co reported no remaining Vertex Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Waters Parkerson & Co sold 489 Vertex Pharmaceuticals shares in Q3 2025, an estimated $218K.
  • Waters Parkerson & Co first reported a position in Vertex Pharmaceuticals in Q2 2024 and held it in 4 quarters.
  • Waters Parkerson & Co's Vertex Pharmaceuticals position peaked at $237K in Q1 2025.
  • 1,519 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2025.

Based on Waters Parkerson & Co's 13F filing for Q3 2025, filed 28 Oct 2025.